🇯🇵 Japan Country × Condition
obesity Clinical Trials in Japan
Active clinical trials for obesity with research sites in Japan. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 3, Phase 1 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇯🇵 Japan
Active Trials in Japan (2)
NCT07684235 Phase 3
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Enrollment
3,200 pts
Country
🇯🇵 Japan
Amgen
View Trial → NCT07693231 Phase 1
Recruiting
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Enrollment
48 pts
Country
🇯🇵 Japan
Boehringer Ingelheim
View Trial → Frequently Asked Questions
How many obesity clinical trials are active in Japan?
There are currently 2 active clinical trials for obesity with sites in Japan, of which 2 are actively recruiting patients.
How can I join a obesity clinical trial in Japan?
To join a obesity clinical trial in Japan, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Japan directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are obesity trials in Japan?
Active obesity trials in Japan span Phase 3, Phase 1. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology